53 results about "Galactosamine" patented technology

The invention relates to the technical field of aquaculture, in particular to a leiocassis longirostris intestinal health functional additive based on spermaceti soxhlet metabolite. The Leiocassis longirostris intestinal health functional additive comprises the following functional components: chondroitin sulfate, N-acetyl-D-galactosamine, 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4'- The composition is prepared from the following raw materials: 4, 6-dihydroxyflavone, polydatin, ascorbic acid, glucoside, arabinogalactan, 3-O-beta-D-galactopyranosyl-L-arabinose, tyramine, 4A-hydroxytetrahydrobiopterin, hyaluronic acid and 3-mercapto-2-butanol. According to the technical scheme, the technical problem that an existing probiotic viable bacterium preparation is difficult to meet the intestinal health management requirement in intensive culture of the leiocassis longirostris can be solved. Compared with the prior art, the scheme is more efficient, stable and safe, healthy development of the Leiocassis longirostris breeding industry can be effectively promoted, and the method has ideal application and popularization prospects.

The disclosure provides methods for synthesis of peracetylgalactosamine-1-pentanoic acid, also called peracetylated D-galactosamine C5 linker or GalNAc C5 linker, using a vegetal source as a starting material, such as vegetal-sourced D-glucosamine or D-glucosamine hydrochloride. Also provided are methods for purifying the peracetylgalactosamine-1-pentanoic acid, or GalNAc C5 linker, thus produced so that the end product comprises fewer impurities.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention relates to the technical field of culture media, and particularly discloses a candida chromogenic culture medium as well as a preparation method and application thereof. The candida chromogenic culture medium disclosed by the invention is prepared from the following components in concentration: 10 to 11 g / L of peptone, 12 to 17 g / L of agar, 7 to 9 g / L of glucose, 1 to 2 g / L of chromogenic substrate and 0.4 to 0.6 g / L of bacteriostatic agent, the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D-galactosamine and 4-methylumbelliferone-beta-D-N-acetyl galactosamine, and the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D- The bacteriostatic agent is prepared by mixing chloramphenicol, taurocholic acid and nalidixic acid. When being used for detecting and identifying candida albicans, candida tropicalis, candida krusei and candida glabrata, the chromogenic culture medium provided by the invention has strong specificity, short identification time and wide practical application value.

The application discloses a preparation method of a liver-targeting drug delivery carrier, and comprises the following steps: synthesizing bromic acid N-acetylgalactosamine ester; and synthesizing the liver-targeting drug delivery carrier. x The liver-targeting drug delivery carrier GalNAc-C x CD is designed based on bromic acid N-acetylgalactosamine ester Br-C GalNAc and beta-cyclodextrin, which can include poorly soluble drugs to be delivered to the liver and released in a targeted manner, greatly improves the targeting efficiency on the liver, and the targeting delivery rate can reach more than 70%, while effectively improving the solubility and bioavailability of the poorly soluble drugs, improving the drug treatment effect, providing a new strategy for the delivery of other poorly soluble drugs for treating liver diseases, and laying a foundation for the development of drugs and functional foods for intervening NASH.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses lake sphingosine bacteria AT4-200, exopolysaccharides thereof and application of the lake sphingosine bacteria AT4-200 in promoting plant growth and improving plant stress resistance, relates to the technical field of microbial technology and biostimulant application, and discloses the lake sphingosine bacteria AT4-200 separated and purified from tobacco rhizosphere and the exopolysaccharides generated by the lake sphingosine bacteria AT4-200, the molecular weight of the exopolysaccharides is about 1340Da, and the exopolysaccharides can be applied to plant growth promotion and plant stress resistance improvement. The polysaccharide mainly comprises five monosaccharides, namely mannose, glucose, glucosamine, galactosamine and rhamnose. Application verifies that the strain and / or exopolysaccharide thereof can significantly increase agronomic characters such as leaf area and dry weight of tobacco, can effectively improve salt tolerance of soybean under salt stress, and can be used as a novel, low-cost and efficient plant biostimulant or stress-resistant preparation.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

We provide a technology that can activate NRF2. [Solution] An NRF2 activator comprising one or more chondroitin sulfate oligosaccharides selected from (a) to (c) below as an active ingredient: (a) a disaccharide having a chondroitin sulfate structure (a disaccharide of CS), (b) a trisaccharide having two N-acetyl-D-galactosamine residues and a chondroitin sulfate structure (a trisaccharide of CS having two GalNac residues), (c) a tetrasaccharide having a chondroitin sulfate structure (a tetrasaccharide of CS). According to the present invention, NRF2 can be activated. This is expected to promote homeostatic reactions in the body, such as antioxidant reactions, anti-inflammatory reactions, and detoxification reactions, and contribute to maintaining and improving health. It is also expected to contribute to the prevention and improvement of various unhealthy conditions and diseases caused by oxidative stress, inflammation, and toxic chemicals.

Disclosed is a method for preparing an N-acetyl-D-galactosamine tripolymer precursor. In the preparation of the tripolymer precursor, a compound 4 is prepared by the following steps: adding a compound 3, a 4 Å molecular sieve powder, and a reaction solvent into a reactor; inflating and changing protective gas for 3 times; stirring; firstly adding an enol, followed by slowly dropping trimethylsilyl trifluoromethanesulfonate; after a reaction, quenching the reaction with an alkali solution; and performing extraction, separating liquid, washing, drying, filtration, etc., so as to obtain the compound 4. According to the present disclosure, the problems of various production processes, more times of column chromatography for purification of products accompanied by lower yields in the prior art are solved.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and / or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

The invention discloses an oxygen / nitrogen-rich organic molecule functionalized graphene oxide composite material as well as preparation and application thereof, and relates to the field of nano composite materials. The composite material comprises a substrate and oxygen / nitrogen-rich organic molecules which are connected through a grafting reaction. The preparation method comprises the following steps: S1, uniformly dispersing graphene oxide in anhydrous N, N-dimethylformamide (DMF) to obtain a graphene oxide dispersion liquid; and S2, uniformly mixing the obtained graphene oxide dispersion liquid with D-galactosamine hydrochloride, and carrying out amidation reaction under a catalytic condition to obtain the oxygen / nitrogen-rich organic molecule functionalized graphene oxide composite material. The composite material can be used as an adsorbent for adsorbing phenolic pollutants, shows excellent adsorption selectivity to 1-naphthol, can efficiently enrich and separate low-concentration 1-naphthol, has good reusability, and has wide application prospects in the adsorption separation process of wastewater treatment.

The present invention relates to a method for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleotide diphosphates, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleotide diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleotide diphosphate. The synthesis method according to the present invention is characterized by high efficiency and high yield. Another part of the present invention is a key intermediate of the method.

The invention relates to a novel process for generating N-acetylgalactosamine (GalNAc) clusters using a nitrilase and conjugating said GalNAc clusters to oligonucleotides, such as oligonucleotides for use in therapy. In particular, the nitrilase is used to catalyse the conversion of a trinitrile intermediate to a triacid intermediate.

The invention relates to uridine diphosphate-N-difluoroacetyl galactosamine as well as a preparation method and application thereof. The chemical structure of the UDP-GalNDFA is similar to that of a natural substrate UDP-GalNAc, and the core difference is that N-acetyl at the site 2 of the UDP-GalNDFA is replaced by N-difluoroacetyl. The preparation method comprises the following steps: (1) preparing difluoroacetyl galactosamine; and (2) preparing the UDP-GalNDFA by taking the difluoroacetyl galactosamine as a substrate. As a novel artificial donor sugar, the UDP-GalNDFA has the characteristics of high activity, difficulty in hydrolysis and capability of being artificially synthesized. Compared with the existing donor sugar UDP-GalNTFA, the glucose UDP-GalNTFA has higher catalytic activity on glycosyl transferase, has stronger stability, is not easy to hydrolyze, and can be used as a donor substrate for synthesizing a chondroitin oligosaccharide skeleton, a chondroitin oligosaccharide intermediate and a chondroitin oligosaccharide derivative by a chemical enzyme method.

The invention discloses a method for detecting a soil microbial marker-amino sugar by direct ion chromatography, and relates to the technical field of biomarker analysis, and the method comprises the following steps: adding a soil sample into a 6mol / L hydrochloric acid solution, and hydrolyzing at 105 DEG C for 8 hours; drying the hydrolysate with nitrogen, redissolving with ultrapure water, centrifuging, taking supernate, and filtering with a 0.22 mu m filter membrane to obtain a to-be-detected solution; the method comprises the following steps: injecting a to-be-detected solution into an ion chromatography system provided with an electrochemical detector, and carrying out gradient elution by adopting an anion exchange chromatographic column and taking a mixed solution of sodium hydroxide and sodium acetate as a mobile phase to realize separation and quantitative detection of glucosamine (GlcN), galactosamine (GalN), aminomannose (ManN) and muramic acid (Mur). A highly toxic derivatization step necessary for a traditional method is omitted, a sample can be directly injected through three-step purification after acid hydrolysis, and efficient separation of four amino sugars is realized by matching with a special ion chromatography system.

Described herein is a beta-glycoside of structural formula (I) wherein X1 or X2 is-C (= O) OR, R is an alkyl group comprising from 1 to 6 (1 to 4) carbon atoms, and Y is a monovalent sugar selected from the group consisting of beta-D-glucose, beta-D-galactose, beta-D-glucuronic acid, N-acetylglucosamine or galactosamine, where when X1 is-C (= O) OR then X2 is-H, and when X2 is-C (= O) OR then X1 is-H. Such beta-glycosides can be used as indicators, such as biological indicators. (I)

The present application relates to compounds of N-acetylgalactosamine (GalNAc) origin and oligonucleotides. Provided herein are compounds of N-acetylgalactosamine (GalNAc) origin, modified oligonucleotides, and methods of modulating protein function and treating diseases, disorders, and symptoms in a subject.

The invention discloses a method for producing N-acetylgalactosamine sulfate by degrading chondroitin sulfate through two-step enzyme catalysis, and belongs to the technical field of biology. The preparation method comprises the following steps: firstly, splitting chondroitin sulfate by using lyase to generate unsaturated chondroitin sulfate disaccharide, and then reacting the obtained unsaturated chondroitin sulfate disaccharide with disaccharide hydrolase; enabling an unsaturated bond to break and hydrolyze to generate two monosaccharides, namely N-acetyl galactosamine sulfate (monosaccharide) and 4-deoxy-L-threo-5-hexanone uronic acid; and finally, separating the N-acetyl galactosamine sulfate (monosaccharide) from the 4-deoxy-L-thre-5-hexuronic acid by virtue of strong anion exchange column chromatography, collecting an elution peak, and carrying out freeze-drying, so as to obtain the high-purity N-acetyl galactosamine sulfate. The method provided by the invention is green and environment-friendly, has strong specificity and high conversion rate, is suitable for industrial application, can be widely applied to the fields of medicines and health care products, and has important market value.

The invention belongs to the field of molecular biology and genetic breeding, and relates to screening of a group of SNP (Single Nucleotide Polymorphism) sites related to gonad development traits of crassostrea gigas and application of the SNP sites in evaluating gonad development level. Four SNP molecular marker loci significantly related to gonad development traits are disclosed by performing whole genome association analysis on a large-scale group of crassostrea gigas, the four SNP molecular marker loci are respectively located in Region1 (BP10, embryo protease 10) and Region2 (GALNT5, polypeptide N-acetylgalactosamine transferase 5) gene regions, and dominant genotypes and dominant genotype combinations of the SNP loci are determined. The SNP molecular marker combination is used for prediction and auxiliary breeding of the gonad development level of the crassostrea gigas, early-stage, lossless and high-throughput screening of individuals with the high gonad development level can be achieved, and the breeding efficiency of breeding traits of the crassostrea gigas is remarkably improved.

The application discloses a marine red alga polysaccharide extract and application thereof, and belongs to the technical field of marine organisms and medicines. Gigartina radula The polysaccharide extract is extracted from marine red algae, and the main component is natural galactosamine sulfate, contains galactose and glucose, has a sulfate content of 20-40%, a 3,6-endo ether galactose content of 20-50%, and a viscosity of 80-400 mPa s. The polysaccharide extract contains kappa-carrageenan structural units, iota-carrageenan structural units, mu-carrageenan structural units, nu-carrageenan structural units and lambda-carrageenan structural units, and the proportion of the lambda-carrageenan structural units is 10-50%. The marine red alga polysaccharide extract can be applied to the preparation of medicines or functional skin care products for preventing and / or treating inflammatory and immune-related skin diseases such as atopic dermatitis AD.

This invention relates to a lactic acid bacteria extracellular polysaccharide and its application in enhancing the gastrointestinal barrier function of lambs. The lactic acid bacteria extracellular polysaccharide is composed of glucosamine, arabinose, galactosamine, galactose, glucose, mannose, and glucuronic acid. This invention also provides the application of the lactic acid bacteria extracellular polysaccharide in the preparation of formulations to enhance the gastrointestinal barrier function of lambs and as a feed additive for ruminants. This lactic acid bacteria extracellular polysaccharide can effectively reduce gastrointestinal abnormalities, edema, ulcers, erosions, and inflammatory cell infiltration in newborn lambs, greatly improving their gastrointestinal defense function, perfecting their inherent defense mechanisms, enhancing their intestinal disease resistance and overall health, and shifting the treatment of intestinal inflammation and disease from passive to proactive intervention, demonstrating great potential for development and application.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The application discloses a marine-derived compound Cpd-8 and application thereof in preparation of a medicine for resisting TNF-induced cell death. Through screening of an extract library of marine-derived sponge symbiotic fungi of a research group, a small-molecule inhibitor with a novel structure is obtained, which can resist TNF-induced cell death, and specifically, the marine-derived sesquiterpene lactone nitrobenzene analogue Cpd-8 and a pharmaceutically acceptable salt thereof. The compound can inhibit TNF-induced cell death and formation of a complex II in a signal pathway, thereby exerting an anti-cell death activity. In-vitro cell experiment results show that the compound of the application can significantly inhibit TNF-induced cell death. In-vivo animal experiment results show that the compound of the application can inhibit TNF-alpha / D-GaIN (D-galactosamine)-induced acute liver injury, and significantly prolong the survival period of mice.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit mitochondrial amidoxime reducing component 1 (MARC1) gene expression. Also disclosed are pharmaceutical compositions that include MARC1 RNAi agents and methods of use thereof. The MARC1 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the MARC1 RNAi agents in vivo provides for inhibition of MARC1 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by MARC1 gene expression, including nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1-related disease.